A
AdipoPharma
Development of a first-in-class drug for type 2 diabetes, targeting adipocyte cells to reverse insulin resistance
About AdipoPharma
AdipoPharma is a French biotechnology company that is developing a novel drug for the treatment of type 2 diabetes. The company's approach focuses on the role of adipocyte cells in the regulation of lipid biosynthesis and the management of lipids throughout the body. By targeting these cells, AdipoPharma aims to develop a therapy that can reverse insulin resistance, a key factor in the development of type 2 diabetes.
Read full description
The company's business model is centered on the research and development of its lead drug candidate. AdipoPharma has successfully secured Series A funding, which will be used to advance its first-in-class compound into clinical trials. The company's target market includes individuals with type 2 diabetes and other metabolic diseases. As a biotechnology firm, its clients are investors and potential partners in the pharmaceutical industry for licensing or acquisition. The company's revenue will be generated through these partnerships and, eventually, from the sale of its approved drug.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Strasbourg, France
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 76.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Diabetes, Biotechnology, Drug Development, Spinout, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, observatoire industrial tech
- Business model
- Manufacturing
- Client focus
- b2b, b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Nov 2024 | $0 | — | Okeanos · Sambrinvest · Newton BioCapital · Good Growth Capital | ↗ |
| SERIES A✓Equity / VC | Jan 2023 | — | — | Good Growth Capital · Newton BioCapital | ↗ |
Growth signals
Latest recorded traffic for AdipoPharma is 1.4K monthly website visits, up 44.3% over the last three months. AdipoPharma's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 VAXXELVaxxel develops novel and proprietary live-attenuated vaccines candidate against respiratory infections |
Villeurbanne, France | Operational | 10 | $1.3M | $5.3M |
 Qubit PharmaceuticalsQuantum physics and AI-driven drug discovery platform |
Paris, France | Operational | |||
 DiogenXBeta-Cell recovery to counter diabetes |
Marseille, France | Operational | |||
 Aelis FarmaBiotech company conducting research and development on innovative signaling specific drugs |
Bordeaux, France | Operational | |||
 Seekyo TherapeuticsA privately-owned biotech company developing a Smart Chemotherapy, selective to tumours, safe for patients |
Saint-Maur-des-Fossés, France | Operational | |||
 MedinCellDevelops therapeutic solutions based on proprietary copolymers and a biocompatible solvent |
Jacou, France | Operational | |||
 CellectisDeveloping allogeneic CAR-T cells |
Paris, France | Operational | |||
 DBV TechnologiesEpicutaneous immunotherapy patch for treating food allergies. |
Châtillon, France | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Bpifrance
Newton BioCapital
Good Growth Capital
Okeanos
Sambrinvest
Orsa
Other known investors3 additional known investors
SATT Conectus
University of Strasbourg
Capital Grand Est
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AdipoPharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AdipoPharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.